DLP-114-Top.jpg

DLP-114 – Risperidone 3-6 month Formulation

Delpor’s DLP-114 is a 3-6 month formulation of Risperidone. The product is using Delpor’s ProzorTM technology and the medication is released from Delpor’s subcutaneous implant device. The system enables zero order release kinetics and it is expected to maintain therapeutic levels of Risperidone and its active metabolite in human plasma. Delpor has already completed several in vivo studies illustrating the performance and the safety of the system.

Comments are closed.